Pepdexpepdex
Stack
← Back to peptides
Comparison

VK2735 vs Semaglutide

VK2735 vs Semaglutide (Ozempic / Wegovy): investigational dual GLP-1/GIP (with an oral form) vs the approved GLP-1 standard. Effect, availability, and the pill angle.

The verdict

Different stage, and that is the whole story. Semaglutide is the approved, widely used GLP-1 you can get today. VK2735 is a dual GLP-1/GIP agonist still in trials (the injectable is in Phase 3, the oral form is heading toward Phase 3 around late 2026, with readouts not before 2027). VK2735 draws attention mainly for its oral version, a once-daily pill that landed near injectable results in early trials. If you want something real and available now, Semaglutide is the only one of the two you can actually get. VK2735 is a watch-this-space, and with an investigational compound, source quality is the real risk.

№ 004
VK2735
Fat LossEvidence: Moderate

VK2735 is an experimental weight-loss drug from Viking Therapeutics. It works on two gut-hormone receptors (GLP-1 and GIP) to cut appetite, the same combo as Tirzepatide. The notable part is the pill version: in early trials a once-daily tablet got close to the results of the injection. It is still in testing and not approved.

Onset
80
Documentation
95
Side intensity
100
Popularity
55
№ 010
Semaglutide
Fat LossEvidence: Strong

Semaglutide is the first wave of modern weight-loss drugs, sold as Ozempic and Wegovy. Single-receptor version of Tirzepatide. Slightly less effective and slightly rougher side effects, but well-studied and widely available.

Onset
80
Documentation
95
Side intensity
82
Popularity
92
Side-by-side
Field
Left
Right
Category
Fat Loss
Fat Loss
Half-life
Long-acting; dosed once-weekly (subcutaneous) in trials
~7 days
Route
Subcutaneous (weekly) or oral (daily), both investigational
Subcutaneous
Schedule
Weekly (injectable) or once-daily (oral) in trials
Once weekly
Cycle length
Trial protocols ran 13 weeks; no established real-world cycle
Open-ended, titrate over months
Dose
No approved human dosing. In Phase 2, the injectable (the VENTURE program) was titrated weekly and an oral Phase 2 ran once-daily, both over 13 weeks. Outside a clinical trial there is no established protocol, and access is trial-only.
Start 0.25mg weekly. Titrate every 4 weeks. Common max 2.4mg.
FDA
Investigational. The injectable is in Phase 3 (begun 2025); the oral form is expected to enter Phase 3 around late 2026. Pivotal readouts are not expected before 2027. Not approved.
Approved as Ozempic (2017, type 2 diabetes), Rybelsus (2019, oral), and Wegovy (2021, obesity).
WADA
Not listed
Not listed
Natty?
Not natty
Not natty
Prescribed
Not available by prescription. Access is trial-only through Viking Therapeutics' clinical program.
Yes, extremely widely prescribed. Insurance coverage variable for weight-loss indication.
Top side effects
Nausea (most common, usually mild to moderate); Vomiting; Diarrhea or constipation
Nausea (often more than tirzepatide); Constipation; Fatigue

Which one should you pick?

Pick VK2735 if people following the oral-glp-1 race who want a needle-free option or users tracking next-generation weight-loss compounds before approval.

Pick Semaglutide if beginners to glp-class peptides or users with insurance coverage on wegovy / ozempic.

AI Coach · free

Still torn between VK2735 and Semaglutide?

The AI Coach reads both, asks about your goal and experience, and tells you which one actually fits — plus how to dose and stack it. Free.

Ask the Coach: VK2735 vs Semaglutide →
Full entry
№ 004 VK2735 →
Full entry
№ 010 Semaglutide →